Best Genomics Companies in Israel
The 99 best Genomics companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kaiima.
Ranking the best Genomics companies in Israel by disclosed equity funding gives you a concrete way to measure where serious capital is actually landing in one of the world's more quietly productive biotech corridors. Ninety-nine companies tracked, $720M in total disclosed funding, and not a single unicorn yet — which tells you something real about where this ecosystem sits on the maturity curve. The global genomics market was valued at roughly $24.3B in 2021 and is forecast to reach $85.1B by 2030 at a 16.37% CAGR, driven by falling sequencing costs and accelerating demand for personalized medicine. Israel's cohort is early-stage heavy, but the funding concentration is sharp: Oncohost alone accounts for $43M, dwarfing the rest of the top five combined.
So what's actually moving here? Machine learning drug discovery and pharmacogenomics are drawing the most coverage momentum, and hereditary disease genomics is a recurring theme among the funded names. I'd watch Cassidy Bio and Pepticom, both at $8M, as the clearest signals of where institutional appetite sits below the Oncohost tier. Investors like aMoon and Arkin Holdings aren't writing checks casually in this space. The pre-unicorn status isn't a warning sign — it's a baseline, and the structural tailwinds behind sequencing economics suggest the gap between current valuations and exit scale won't stay this wide indefinitely.
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Israel
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kaiima Developer of plant genetics and breeding technology | $91M | 153 mo ago | 24 | Doron Gal ex-CEO | — | — | — | 1 partnership |
| 2 | Nucleix Developer non-invasive molecular cancer diagnostic tests | $88M | 53 mo ago | 62 | — | WordPressApple iCloud MailMicrosoft 365+24 | Top 50M | 163 patents Epigenetic DNA methylation profiling for cancer and prenatal liquid biopsy diagnostics. | — |
| 3 | NovellusDx Developer of technology for precision cancer diagnosis and therapies | $86M | 69 mo ago | 49 | — | — | — | 46 patents Patient-specific cancer mutation identification, functional validation, and drug response profiling | — |
| 4 | Equinom AI-powered grain optimization for smarter milling and enhanced food production | $71M | 42 mo ago | 43 | Gil Shalev Founder & CEO | Webflowcore-jsjQuery+16 | Top 50M | — | 1 launch |
| 5 | Emendo Biotherapeutics Provider of re-designed gene-editing tools as drugs for genetic disorders | $61M | 77 mo ago | 116 | Shilo Ben Zeev Co-Founder | WordPressMySQLPHP+23 | Top 50M | — | — |
| 6 | BioSight Developer of therapeutics for oncology & hematological disorders | $59M | 66 mo ago | 10 | — | — | — | 90 patents Prodrug conjugates of cytarabine with amino acids for targeted cancer chemotherapy | — |
| 7 | MyHeritage Provider of tools for creating family trees and exploring ancestry | $49M | 162 mo ago | 518 | — | WordPressApple iCloud MailMySQL+36 | Top 10k | — | — |
| 8 | ONCOHOST AI-based oncology therapy plan solution for professionals 64Patents top 27%Moat top 28%Talent top 28%Innovation top 29% All 10 signals ▾Patentstop 27% Moattop 28% Talenttop 28% Innovationtop 29% AItop 30% Fundingtop 31% Techbottom 42% Marketbottom 41% Globalbottom 35% Newsbottom 18% Patents: 55 patents matched (strict assignee match) · 38 filings since 2022 vs 17 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 55 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $43M | 13 mo ago | 48 | Yuval Shaked Co-Founder | Cart FunctionalityWebflowSalesforce+11 | Top 50M | 55 patents AI-driven predictive analytics for personalized cancer treatment response and biomarker identification | 2 job openings |
| 9 | Metabomed Developer of targeted therapies to treat cancer | $36M | 78 mo ago | 7 | — | — | — | 53 patents ACSS2 enzyme inhibitors for metabolic and oncology drug development | — |
| 10 | Biomica Developer of microbiome-based therapeutics to treat immune-mediated and infectious diseases | $20M | 37 mo ago | 15 | Elran Haber CEO | WordPressMySQLPHP+16 | Top 50M | 38 patents Therapeutic and diagnostic microbial consortia for human health applications | — |
| 11 | Igentify Provider of digital healthcare solutions and screening genetic tests | $16M | 81 mo ago | 66 | — | WordPressMySQLPHP+21 | Top 50M | 11 patents Adaptive speech gap modulation technology and distributed genomic data storage solutions. | — |
| 12 | Lavie Bio Provider of microbiome-based agricultural biological products for improving food quality, sustainability, and… | $10M | 45 mo ago | 23 | Ofer Haviv CEO | WordPressMySQLPHP+15 | Top 10M | 37 patents Microbial biocontrol agents and formulations for crop disease and pest management | — |
| 13 | Geneyx Provider of a clinical genetics data management platform for hospitals and genetic labs | $10M | 55 mo ago | 31 | — | WordPressBetterDocsMySQL+37 | Top 10M | — | — |
| 14 | Cassidy Bio Developer of an AI-powered platform for therapeutic-grade gene editing design 69Talent top 28%AI top 45%Funding top 47%Global bottom 48% All 4 signals ▾Talenttop 28% AItop 45% Fundingtop 47% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-powered rank vs industry peers · Fliar Intelligence Index 69/100 | $8M | 7 mo ago | — | Yaniv Shmueli Co-Founder & CTO | — | — | — | — |
| 15 | Pepticom Developer of AI-based technology for the discovery of peptide drug candidates 35Moat top 31%Growth top 35%Product top 36%AI top 45% All 10 signals ▾Moattop 31% Growthtop 35% Producttop 36% AItop 45% Techbottom 46% Patentsbottom 45% Fundingbottom 40% Globalbottom 40% Innovationbottom 37% Marketbottom 29% Moat: Editorial + unicorn rating 7/10 · IP moat: 15 patents Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 35/100 | $8M | 17 mo ago | 18 | — | WordPressMySQLPHP+20 | Top 50M | 15 patents Patents concentrated in health & consumer products | — |
| 16 | Todos Medical Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders | $7M | 56 mo ago | 7 | — | — | — | 42 patents Blood-based infrared spectroscopy for Alzheimer’s and cancer biomarker detection | — |
| 17 | Senseera Provider of liquid biopsy blood tests for cancer diagnosis 35Talent top 28%Funding top 46%Market bottom 37%Global bottom 36% All 4 signals ▾Talenttop 28% Fundingtop 46% Marketbottom 37% Globalbottom 36% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $7.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $7M | 17 mo ago | — | Nir Friedman Co-Founder | — | — | — | — |
| 18 | Glycominds Personalized disease management solution | $7M | 295 mo ago | 6 | — | — | — | 75 patents Diagnostic biomarkers and immunoassay methods for multiple sclerosis and Crohn's disease | — |
| 19 | Pigmentum Developer of genetically modified plants producing natural compounds | $7M | 40 mo ago | 9 | Tal Lutzky Co-Founder & CEO | — | — | — | — |
| 20 | BetterSeeds Developer of a genome editing platform to improve crop resilience and yields for sustainable agriculture | $7M | 45 mo ago | 21 | Tal Sherman Co-Founder | — | — | 76 patents Genetic editing of crops for allergen reduction, yield, and stress resilience | — |
| 21 | VBL Therapeutics Developing gene and small molecule therapies for cancer and inflammation | $7M | 50 mo ago | 7 | — | — | — | — | — |
| 22 | Trobix Bio Developer of microbiome-based therapeutics that address various therapeutic areas | $6M | 38 mo ago | 9 | — | — | — | — | — |
| 23 | Genome Compiler Corporation Provider of DNA design & visualization, data management and collaboration | $5M | 152 mo ago | 22 | Omri Amirav-Drory Founder & CEO | — | — | 2 patents Software platform for designing, visualizing, and ordering synthetic DNA constructs | — |
| 24 | IdentifAI Provider of a non-invasive prenatal screening test for genetic syndromes | $3M | 18 mo ago | 12 | Tom Rabinowitz Co-Founder And Cto | — | — | — | 1 job opening · 1 award |
| 25 | Evogene Developer of computational tools for pharmaceutical and agricultural industries | $2M | 37 mo ago | 137 | — | WordPressMySQLPHP+22 | Top 10M | 1,226 patents Genetically engineered plant traits for enhanced yield, biomass, nitrogen use, and stress tolerance | 1 partnership |
| 26 | miCure Therapeutics Developer of microRNA therapeutics and diagnostics for CNS disorders | $2M | 144 mo ago | — | Michel Horovitz CEO | — | — | 8 patents Targeted microRNA therapeutics and neuron-specific oligonucleotide delivery platforms | — |
| 27 | TargetGene Biotechnologies Platform for in-vivo assembling of nucleases in plant cells | $930K | 38 mo ago | 6 | Dan Weinthal Co-Founder And Coo | — | — | 46 patents CRISPR-based gene editing platforms for immune cell engineering and targeted DNA modification | — |
| 28 | Rosetta Green Provider of tech news, computer repair tips, and gadget information | $814K | 178 mo ago | — | Aviad Friedman Chairman & CEO | — | — | 12 patents Genetically engineered crops improving oil yield, stress tolerance, and nitrogen efficiency | — |
| 29 | LipoMedix Provider of Israeli clinical-stage biotech developing PEG-ylated liposomal Mitomycin drugs for cancer | $639K | 78 mo ago | — | Alberto Gabizon Founder & CEO | — | — | — | — |
| 30 | Minovia Therapeutics Provider of cell therapy treatment for mitochondrial disease | $616K | 9 mo ago | 32 | Natalie Yivgi-Ohana CEO | WordPressMySQLPHP+18 | Top 10M | 146 patents Therapeutic delivery of functional mitochondria via stem cells for disease treatment | — |
| 31 | Pronto Diagnostics Provider of molecular diagnostic products and services | $552K | 101 mo ago | 19 | — | WordPressMySQLPHP+9 | Top 50M | — | — |
| 32 | Phenome Networks Developer of software for plant breeding and variety testing processes | $510K | 68 mo ago | 25 | — | WordPressMySQLPHP+31 | Top 5M | — | — |
| 33 | MataGene Biotechnology company offering technology to enhance crop photosynthesis using genetic engineering | $250K | 46 mo ago | — | Vivekanand Tiwari Co-Founder | — | — | — | — |
| 34 | ZMD Group Provider of microbiome-based therapeutics and diagnostics | $118K | 93 mo ago | — | Barak Zigdon Co-Founder & CEO | — | — | — | — |
| 35 | NextFerm Provider of non-GMO technology for improved yeast strains | $111K | 77 mo ago | 30 | Boaz Noy Chief Executive Officer | — | — | — | — |
| 36 | Breedit Provider of data recording and analysis platform for plant breeders | $111K | 120 mo ago | — | Oded Sagee Founder & CEO | — | — | — | — |
| 37 | Magentiq Eye Computer vision technology in endoscopic procedures | $100K | 10 mo ago | 14 | — | WordPressMySQLPHP+13 | Top 50M | 17 patents AI-driven computer‑aided detection and analysis of colonoscopic images for polyp identification | — |
Top 12 Genomics companies in Israel
#1
Series C · Binyamina Giv at Ada, Haifa District · founded 2017 · 48 employees$43Mraised▾
AI-based oncology therapy plan solution for patients and professionals. The company has developed a proprietary proteomic analysis that can analyze the proteomic changes in the blood sample induced by the patient in response to cancer therapy. The company also provide treatment strategy to improve the effectiveness of therapy. It also provides consultancy services to patients, oncologists, nurses, and pharma companies among others. The company has developed PROphet which is a bioinformatics tool used to identify proteomic patterns related to therapy.
- May 2025Grant (prize money)$2.8M
- May 2022Series C$35M
- Jan 2021Series B$8M
- Jan 2020Grant (prize money)—
#2
Seed · Tel Aviv, Tel Aviv · founded 2024$8Mraised▾
Developer of an AI-powered platform for therapeutic-grade gene editing design. The platform uses a genomic foundation model to predict efficacy, safety, and repair outcomes. It assists in selecting guides, editors, and contexts for therapeutic gene editing. The platform also validates experimental results to strengthen predictive power.
- Nov 2025Seed$8M
#3
Series A · Jerusalem, Jerusalem District · founded 2011 · 18 employees$7.6Mraised▾
Developer of AI-based technology for the discovery of peptide drug candidates. The platform's technology is an algorithm that assists in protein-protein interface and peptide-protein interface enabling the design of binding peptides, agonists, and antagonists that are intended to block protein-protein interactions. It analyzes the target surface surrounding the desired binding area and then performs a design process to provide a peptide library with optimal binding affinity.
- Jan 2025Series A$6.6M
- Mar 2021Series A$2.6M
- Oct 2019Series A$5M
- Aug 2013Seed—
#4
Seed · Jerusalem, Jerusalem District · founded 2020$7.1Mraised▾
Provider of liquid biopsy blood tests for cancer diagnosis. The cfChIP-seq technology can detect cell-free chromatin tissue which can be used to identify patient-specific gene expression for the detection of diseases and treatment response. The company uses molecular biology, next-generation sequencing, and computational analysis to extract epigenetic information.
- Jan 2025Seed$7.1M
#5
Funding Raised · Tirat Carmel, Haifa District · founded 2011 · 32 employees$616.1Kraised▾
Minovia provides cell therapy treatment for mitochondrial disease. The company uses Mitochondria Augmentation Therapy (MAT) a proprietary method of isolating mitochondria from white blood cells or placentas. The placental blood of women is used to extract mitochondria, then the cell collection is done, and after that apheresis where doctors can select hematopoietic stem cells from the white blood cells collected and then, over 24 hours, introduce the healthy mitochondria to the stem cells.
- Aug 2025Grant (prize money)$350K
- Oct 2022Grant (prize money)$266.1K
#6
Series A · Tel Aviv, Tel Aviv · founded 2020 · 12 employees$3.3Mraised▾
Provider of a non-invasive prenatal screening test for genetic syndromes. It features proprietary data science algorithms and bioinformatics technology that give an overview of the health of the fetus at an early stage of pregnancy.
- Dec 2024Series A$6.5M
- Dec 2024Grant (prize money)—
- Mar 2023Seed$3.3M
#7
Series D · Rehovot, Central District · founded 2012 · 43 employees$71Mraised▾
AI-powered grain optimization for smarter milling and enhanced food production. They are revolutionizing the food industry by developing and optimizing grain crops using cutting-edge AI technology. Their Manna™ AI software empowers millers, traders, and ingredient processors to make informed decisions, improve purchasing power, enhance storage efficiency, and boost processing output. This SaaS platform analyzes grain properties, predicts performance, and provides actionable insights to save money, predict quality, boost operational efficiency, and reduce risk. They also breed innovative non-GMO crop varieties to meet specific food industry needs, driving food innovation from plant to plate. Their solutions optimize protein-crop processing and wheat baking quality, shaping the grain value chain with data-driven insights and precision.
- Dec 2022Series D$35M
- Jun 2021Series C$20M
- Jan 2020Grant (prize money)$160.8K
- Dec 2019Series B$10M
#8
Series A · Haifa, Haifa District · founded 2015 · 14 employees$100Kraised▾
Magentiq Eye provides software based on computer vision and machine learning technology to provide assistance to doctors in performing medical procedures. Its current portfolio includes software that assist in detection of colon cancer through colonoscopy and endoscopy.
- Jul 2025Series A—
- Jul 2019Grant (prize money)$55.7K
- Feb 2019Grant (prize money)$57.3K
- Jun 2016Seed$100K
#9
Series C · Rehovot, Central District · founded 2008 · 62 employees$88.5Mraised▾
Developer non-invasive molecular cancer diagnostic tests. The company uses DNA methylation patterns (epigenetics) to detect cancer using proprietary biomarker assays. Its first product, the Bladder EpiCheck is used to diagnose bladder cancer. In addition, the company has developed diagnostic tests for colorectal cancer and lung cancer.
- Dec 2021Series C$22M
- Apr 2021Grant (prize money)$60.6K
- Apr 2021Series C$55M
- Nov 2018Grant (prize money)$2.8M
#10
Series B · Rehovot, Central District · founded 2017 · 15 employees$20Mraised▾
Developer of microbiome-based therapeutics to treat immune-mediated and infectious diseases. The company uses PRISM a proprietary computational analysis and predictive capabilities to identify BMC128 a combinational therapy for Non-small-cell lung carcinoma. Also, it develops drug candidates for multi drug-resistant organisms and gastrointestinal diseases.
- Apr 2023Series B$20M
#11
Series C · Jerusalem, Jerusalem District · founded 2011 · 49 employees$85.5Mraised▾
Developer of technology for precision cancer diagnosis and therapies. The company's technology allows monitoring the outcomes of known and unknown DNA mutations, the function & clinical significance of each mutation, and the activity of the drug(s) on a specific tumor.
- Sep 2020Series C$57M
- Apr 2018Series B$6M
- Jun 2016Series B$12.5M
- Dec 2015Series A$10M
#12
Acquired · Karmiel, North District · founded 2000 · 10 employees$59Mraised▾
Developer of therapeutics for oncology & hematological disorders. The company's lead product is aspacytarabine (BST-236) an anti-metabolite for Adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Dec 2020Series C$27M
- Mar 2020Series C$19M
- May 2016Series A$13M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.